GYRE

GYRE

USD

Gyre Therapeutics Inc. Common Stock

$7.290-0.180 (-2.410%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$7.470

高値

$7.470

安値

$7.250

出来高

0.06M

企業ファンダメンタルズ

時価総額

662.1M

業種

バイオテクノロジー

United States

取引統計

平均出来高

0.09M

取引所

NCM

通貨

USD

52週レンジ

安値 $6.11現在値 $7.290高値 $19

関連ニュース

GlobeNewswire

Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by

もっと見る
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
GlobeNewswire

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025

SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems

もっと見る
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
Analyst Upgrades

Jefferies Initiates Coverage On Gyre Therapeutics with Buy Rating, Announces Price Target of $16

Jefferies analyst Roger Song initiates coverage on Gyre Therapeutics with a Buy rating and announces Price Target of $16.

もっと見る
Jefferies Initiates Coverage On Gyre Therapeutics with Buy Rating, Announces Price Target of $16